Acquisition by Robert DeLuccia of 19737 shares of Acurx Pharmaceuticals at 3.8 subject to Rule 16b-3
| ACXP Stock | USD 1.25 0.10 8.70% |
Slightly above 55% of Acurx Pharmaceuticals' retail investors are presently thinking to get in. The analysis of overall sentiment of trading Acurx Pharmaceuticals LLC stock suggests that some investors are interested at this time. Acurx Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Acurx Pharmaceuticals LLC. Many technical investors use Acurx Pharmaceuticals LLC stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Acurx |
Filed transaction by Acurx Pharmaceuticals LLC Director, 10 Percent Owner . Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Acurx Pharmaceuticals Fundamental Analysis
We analyze Acurx Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acurx Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acurx Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
Acurx Pharmaceuticals is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Acurx Pharmaceuticals LLC Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Acurx Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Acurx Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Acurx Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Acurx Pharmaceuticals Related Equities
| ANTX | AN2 Therapeutics | 21.90 | ||||
| SILO | Silo Pharma | 11.11 | ||||
| MNPR | Monopar Therapeutics | 8.84 | ||||
| ADAG | Adagene | 1.30 | ||||
| PMVP | Pmv Pharmaceuticals | 1.25 | ||||
| RZLT | Rezolute | 1.00 | ||||
| ACRV | Acrivon Therapeutics, | 0.80 | ||||
| ANEB | Anebulo Pharmaceuticals | 0.70 | ||||
| AVTE | Aerovate Therapeutics | 0.38 | ||||
| LUMO | Lumos Pharma | 0.46 | ||||
| MLYS | Mineralys Therapeutics, | 2.59 | ||||
| CADL | Candel Therapeutics | 4.85 |
Additional Tools for Acurx Stock Analysis
When running Acurx Pharmaceuticals' price analysis, check to measure Acurx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acurx Pharmaceuticals is operating at the current time. Most of Acurx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acurx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acurx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acurx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.